Genetic Surgery ― A Right Strategy to Attack CancerSVERDLOV, Eugene D.Current gene therapy. 2011, Vol 11, Num 6, pp 501-531, issn 1566-5232, 31 p.Article

Molecular biology of medulloblastoma : will it ever make a difference to clinical management?GILBERTSON, Richard J; GAJJAR, Amar.Journal of neuro-oncology. 2005, Vol 75, Num 3, pp 273-278, issn 0167-594X, 6 p.Article

Dermatofibrosarcoma protuberans = Dermatofibrosarcoma protuberansUGUREL, S.Hautarzt. 2008, Vol 59, Num 11, pp 933-940, issn 0017-8470, 8 p.Article

Kutane Nebenwirkungen molekular zielgerichteter Therapien = Cutaneous reactions to molecular targeted therapiesPFÖHLER, C; UGUREL, S.Hautarzt. 2008, Vol 59, Num 10, pp 814-820, issn 0017-8470, 7 p.Article

Improving the design of phase II trials of cytostatic anticancer agentsSTONE, Andrew; WHEELER, Catherine; BARGE, Alan et al.Contemporary clinical trials. 2007, Vol 28, Num 2, pp 138-145, issn 1551-7144, 8 p.Article

Receptor tyrosine kinase alterations and therapeutic opportunities in squamous cell carcinoma of the lungDONG WANG; LICHENG DU; QI LIU et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 4, pp 725-731, issn 0344-5704, 7 p.Article

Germ Cell Tumors of the Gonads : A Selective Review Emphasizing Problems in Drug Resistance and Current Therapy OptionsSCHRADER, Mark; KEMPKENSTEFFEN, Carsten; ALBERS, Peter et al.Oncology. 2009, Vol 76, Num 2, pp 77-84, issn 0030-2414, 8 p.Article

Resistance to BRAF-targeted therapy in melanomaSULLIVAN, Ryan J; FLAHERTY, Keith T.European journal of cancer (1990). 2013, Vol 49, Num 6, pp 1297-1304, issn 0959-8049, 8 p.Article

Anti-angiogenic and anti-HER therapyGASPARINI, Giampietro; SARMIENTO, Roberta; LONGO, Raffaele et al.Biomedicine & pharmacotherapy. 2006, Vol 60, Num 6, pp 263-265, issn 0753-3322, 3 p.Conference Paper

Novel treatment strategies for malignant melanoma : A new beginning?KASPER, Bernd; D'HONDT, Veronique; VEREECKEN, Pierre et al.Critical reviews in oncology/hematology. 2007, Vol 62, Num 1, pp 16-22, issn 1040-8428, 7 p.Article

Novel treatment strategies for soft tissue sarcomaKASPER, Bernd; GIL, Thierry; D'HONDT, Veronique et al.Critical reviews in oncology/hematology. 2007, Vol 62, Num 1, pp 9-15, issn 1040-8428, 7 p.Article

A report of three patients treated with Immunocell therapy with imatinib mesylateKANEKO, Toru; GOTO, Shigenori; KUSHIMA, Yoshiaki et al.Anticancer research. 2004, Vol 24, Num 5C, pp 3303-3309, issn 0250-7005, 7 p.Conference Paper

Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy : enhanced effects in vitro and dose-dependent growth delay in vivoMARINI, P; DENZINGER, S; SCHILLER, D et al.Oncogene (Basingstoke). 2006, Vol 25, Num 37, pp 5145-5154, issn 0950-9232, 10 p.Article

Targeted therapy in haematological malignanciesHAMILTON, Ashley; GALLIPOLI, Paolo; NICHOLSON, Emma et al.Journal of pathology (Print). 2010, Vol 220, Num 4, pp 404-418, issn 0022-3417, 15 p.Article

The Role of Kinesin Family Proteins in Tumorigenesis and Progression: Potential Biomarkers and Molecular Targets for Cancer TherapyYUE YU; FENG, Yu-Mei.Cancer. 2010, Vol 116, Num 22, pp 5150-5160, issn 0008-543X, 11 p.Article

Thyroid cancer : The impact of emerging technologies on clinical practice guidelinesMECHANICK, Jeffrey I; CARPI, Angelo.Biomedicine & pharmacotherapy. 2008, Vol 62, Num 8, pp 554-558, issn 0753-3322, 5 p.Conference Paper

Recent developments and current concepts in medulloblastomaGERBER, N. U; MYNAREK, M; VON HOFF, K et al.Cancer treatment reviews. 2014, Vol 40, Num 3, pp 356-365, issn 0305-7372, 10 p.Article

Nanostructures for magnetically triggered release of drugs and biomoleculesBONINI, Massimo; BERTI, Debora; BAGLIONI, Piero et al.Current opinion in colloid & interface science. 2013, Vol 18, Num 5, pp 459-467, issn 1359-0294, 9 p.Article

Imatinib in small cell lung cancerSORIA, Jean-Charles; JOHNSON, Bruce E; LE CHEVALIER, Thierry et al.Lung cancer. 2003, Vol 41, pp S49-S53, issn 0169-5002, SUP1Conference Paper

Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; two case reportsKITAZAKI, Takeshi; FUKUDA, Masaaki; SODA, Hiroshi et al.Lung cancer. 2005, Vol 49, Num 1, pp 125-128, issn 0169-5002, 4 p.Article

Stellenwert neuer Behandlungsansätze mit Targettherapeutika bei malignen Schilddrüsenerkrankungen: Highlights vom ASCO-Kongress 2011 = Current status of therapeutic approaches with targeted therapies in malignant thyroid cancer. Highlights from the 2011 ASCO CongressUECKER, F. C; LABAN, S; KNECHT, R et al.HNO. Hals-, Nasen-, Ohrenärzte. 2012, Vol 60, Num 5, issn 0017-6192, 398, 400-403 [5 p.]Conference Paper

Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)JAHAN, Thierry; LIN GU; KRATZKE, Robert et al.Lung cancer. 2012, Vol 76, Num 3, pp 393-396, issn 0169-5002, 4 p.Article

Will the dark sky over advanced renal cell carcinoma soon become brighter?D'HONDT, V; GIL, T; LALAMI, Y et al.European journal of cancer (1990). 2005, Vol 41, Num 9, pp 1246-1253, issn 0959-8049, 8 p.Article

New targeted treatments in lung cancer: overview of clinical trialsKORFEE, S; GAULER, T; HEPP, R et al.Lung cancer. 2004, Vol 45, pp S199-S208, issn 0169-5002, SUP2Conference Paper

Drug discovery targeting epigenetic codes: The great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosisUNOKI, Motoko; BRUNET, Julie; MOUSLI, Marc et al.Biochemical pharmacology. 2009, Vol 78, Num 10, pp 1279-1288, issn 0006-2952, 10 p.Article